Filgotinib is a JAK1 inhibitor discovered and developed by Galapagos using its target and drug discovery technology platform. It has been developed to treat rheumatoid arthritis (RA) and
Basaglar is indicated to improve glycemic control in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is considered as a biosimilar
The agency has set 15 June 2016 as the action date for Vaxchora BLA. If approved, it would become the only anti-cholera vaccine in the US. PaxVax’s BLA
The company has forged an alliance with Chinese biologics firm WuXi AppTec to produce new biological drugs in the country. AstraZeneca has the option to acquire WuXi AppTec’s
The study, which will evaluate the safety and clinical efficacy of CAM2038 weekly and monthly injections, is a part of the pivotal registration program for which the companies
The drug was already approved for use in boys aged 9 to 15, and for girls and young women aged 9 to 26. Gardasil 9 is indicated to
Boehringer would pay Sanofi €4.7bn as part of the agreement. The French company’s animal-health business has an enterprise value of €11.4bn and Boehringer’s CHC business is valued at
The Wall Street Journal had recently reported that AstraZeneca was looking to acquire Acerta for over $5bn to secure access to its experimental blood cancer drug, acalabrutinib. AstraZeneca
Through the I-O RPM program, BMS and the David Geffen School of Medicine at UCLA will carry out a range of early phase clinical trials. The company will
GSK had regional rights to Amgen’s bone drugs Prolia and Xgeva, as well as cancer drug Vectibix, since 2009 and 2010 respectively. Last year, GSK generated about $111m
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.